Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists

Journal of Medicinal Chemistry

Volumn 45, Issue 18, 2002, Pages 3829-3835

  Murugesan, Natesan ^a   Tellew, John E ^a   Gu, Zhengxiang ^a   Kunst, Bridgette L ^a   Fadnis, Leena ^a   Cornelius, Lyndon A ^a   Baska, Rose Ann F ^a   Yang, Yifan ^a   Beyer, Sophie M ^a   Monshizadegan, Hossain ^a   Dickinson, Kenneth E ^a   Panchal, Balkrushna ^a   Valentine, Maria T ^a   Chong, Saeho ^a   Morrison, Richard A ^a   Carlson, Kenneth E ^a   Powell, James R ^a   Moreland, Suzanne ^a   Barrish, Joel C ^a   Kowala, Mark C ^a   Macor, John E ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' [(2 BUTYL 4 OXO 1,3 DIAZASPIRO[4.4]NON 1 EN 3 YL)METHYL] N (3,4 DIMETHYL 5 ISOXAZOLYL) 2' [(3,3 DIMETHYL 2 OXO 1 PYRROLIDINYL)METHYL](1,1' BIPHENYL) 2 SULFONAMIDE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BMS 193884; BMS 248360; ENDOTHELIN RECEPTOR ANTAGONIST; IRBESARTAN; N ISOXAZOLYLBIPHENYLSULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HYPERTENSION; NONHUMAN; PHARMACOKINETICS; RAT;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHO CELLS; CRICETINAE; CRYSTALLOGRAPHY, X-RAY; ISOXAZOLES; MOLECULAR STRUCTURE; RADIOLIGAND ASSAY; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ENDOTHELIN A; RECEPTORS, ANGIOTENSIN; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0037194633     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020138n     Document Type: Article

References (34)

1. It time for a new approach to the initial treatment of hypertension?
2. The heterogeneity of hypertension: Why does not every patient respond to every antihypertensive drug?
3. Actual blood pressure control: Are we doing things right?
4. Achieving blood pressure targets in the management of hypertension
5. Issues in hypertension: Drug tolerability and special populations
6. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
7. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
8. The renin-angiotensin system: Importance in physiology and pathology
9. Angiotensin II type 1 receptor blockers
10. Nonpeptide angiotensin II receptor antagonists
11. Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy
12. Molecular characterization of endothelin receptors
13. International union of pharmacology. Nomenclature of endothelin receptors
14. Cloning and expression of a cDNA encoding an endothelin receptor
15. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
16. Endothelin receptor antagonists
17. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?
18. An update on the status of endothelin receptor antagonists for hypertension
19. Antihypertensive effects of a mixed endothelin-A- and -B-receptor antagonist, J-104132, were augmented in the presence of an AT1-receptor antagonist, MK-954
20. Hemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats
21. Angiotensin II endothelin-1 receptor antagonists have cumulative hypotensive effects in canine page hypertension
22. Synergistic effects of AT(1) and ET(A) receptor blockade in a transgenic, angiotensin II-dependent, rat model
23. Potent dual antagonists of endothelin and angiotensin II receptors derived from α-phenoxyphenylacetic acids. Part III
24. Shared determinants of receptor binding for subtype selective, and dual endothelin-angiotensin antagonists on the AT1 angiotensin II receptor
25. Biphenylsulfonamide endothelin antagonists: Structure-activity relationships of a series of mono- and disubstituted analogs and pharmacology of the orally active endothelin antagonist 2′-amino-N-(3,4-dimethyl-5-isoxazolyl)-4′-(2-methylpropyl)[1, 1′-biphenyl]-2-sulfonamide (BMS-187308)
26. Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4′-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ETA antagonists
27. Biphenylsulfonamide endothelin receptor antagonists 3. Structure-activity relationship of 4′-heterocyclic biphenylsulfonamides
28. BMS-180560, An insurmountable inhibitor of angiotensin II-stimulated responses: Comparison with losartan and EXP3174
29. Effects of irbesartan on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action
30. Antihypertensive effects of a novel endothelin-A receptor antagonist in rats
31. A new series of imidazolones: Highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists
32. Synthesis of a spheroidal bis-porphyrin: A ligand designed to accept two catalytic metal ions in an isolated environment
33. Convenient synthesis of a novel γ-aminobutyric acid analog: 4-amino-2,2-dimethylbutanoic acid